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Abstract
Radiomics is the high-throughput extraction and analysis of quantitative image
features. For non-small cell lung cancer (NSCLC) patients, radiomics can be applied to
standard of care computed tomography (CT) images to improve tumor diagnosis,
staging, and response assessment.
The first objective of this work was to show that CT image features extracted
from pre-treatment NSCLC tumors could be used to predict tumor shrinkage in
response to therapy. This is important since tumor shrinkage is an important cancer
treatment endpoint that is correlated with probability of disease progression and overall
survival. Accurate prediction of tumor shrinkage could also lead to individually
customized treatment plans.
To accomplish this objective, 64 stage NSCLC patients with similar treatments
were all imaged using the same CT scanner and protocol. Quantitative image features
were extracted and principal component regression with simulated annealing subset
selection was used to predict shrinkage. Cross validation and permutation tests were
used to validate the results. The optimal model gave a strong correlation between the
observed and predicted shrinkages with   0.81.
The second objective of this work was to identify sets of NSCLC CT image
features that are reproducible, non-redundant, and informative across multiple
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machines. Feature sets with these qualities are needed for NSCLC radiomics models to
be robust to machine variation and spurious correlation.
To accomplish this objective, test-retest CT image pairs were obtained from 56
NSCLC patients imaged on three CT machines from two institutions. For each machine,
quantitative image features with concordance correlation coefficient values greater than
0.90 were considered reproducible. Multi-machine reproducible feature sets were
created by taking the intersection of individual machine reproducible feature sets.
Redundant features were removed through hierarchical clustering.
The findings showed that image feature reproducibility and redundancy
depended on both the CT machine and the CT image type (average cine 4D-CT
imaging vs. end-exhale cine 4D-CT imaging vs. helical inspiratory breath-hold 3D CT).
For each image type, a set of cross-machine reproducible, non-redundant, and
informative image features was identified. Compared to end-exhale 4D-CT and breathhold 3D-CT, average 4D-CT derived image features showed superior multi-machine
reproducibility and are the best candidates for clinical correlation.

____________________
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Chapter 1: Introduction
1.1 Background and Significance
Lung cancer is the leading cause of cancer-related mortality both worldwide and in
the United States (1). Over 200,000 new lung cancer cases are diagnosed and over 160,000
people die due to the disease every year in the United States (2).

Non-small cell lung

cancer (NSCLC) accounts for approximately 85% of these lung cancer cases, and overall 5year lung cancer survival is 15% (3). The variation of current incidence rates is primarily
explained by variations in historical tobacco use (4). Therefore, as a result of decreased
tobacco consumption, incidence rates in the United States are declining. However,
worldwide incidence rates are rising rapidly due to increased tobacco use in China and other
developing nations (5).
The tumor node metastasis (TNM) staging system is a systematic way of
representing the spread of lung cancer by assessing tumor size, nodal involvement, and
metastatic extent (6). Staging information is obtained using thoracic computed tomography
(CT) and is often augmented by positron emission tomography (PET) which can detect
metabolically active microscopic disease (7). The three TNM categories can be combined
(i.e. stage grouped) to give an overall tumor stage which has important implications for
treatment and prognosis. Stage I lung cancer is present in the lungs only, stage II has
nearby lymph node involvement, stage III (locally advanced disease) has more distant lymph
node involvement, and stage IV (advanced disease) has additional organ-system
involvement. Surgical resection is recommended for stages I and II, and has relatively good
clinical outcomes. However, approximately 70% of patients present with stage III or stage IV
disease (2). Chemotherapy is generally recommended for stage IV patients, and radiation
with concurrent chemotherapy is recommended for stage III treatment.
At its core, the TNM staging system is an exclusively anatomically-oriented system
that does not take advantage of additional data which may be relevant to prognosis and
treatment, and patients that are assigned the same stage often have large variations in
1

clinical outcome. The addition of information from various non-anatomical sources could help
reduce this problem. For example, the simple physiological features of patient age and body
mass index have been shown to improve NSCLC staging (8). Integration of genetic
information (e.g. single nucleotide polymorphism genotyping) improves the ability to predict
patient survival (9-11), and serum biomarkers have also shown promise for NSCLC
recurrence prediction (12). The literature shows that these and other molecular biomarkers
can be used for indicating etiology, prognosis, and therapy response (13-15). However,
external validation studies for molecular biomarker studies have largely been unsuccessful,
and their clinical application seems stunted (16). This could be due to variations in institution
demographics, sample collection, and/or analysis techniques. Additionally, many solid
tumors are known to be temporally heterogeneous (i.e. genotype changes through time)
and/or spatially heterogeneous (i.e. genotype varies spatially within the tumor). Therefore, a
biopsy sampling a random spatial sub-region of a tumor at a single time point may not be
able to accurately reflect true complexity of the tumor (17).
In light of these complications, CT imaging seems like a viable alternative for probing
the information content of tumors. CT imaging is readily available, and any additional
information gleaned from imaging is essentially “free” since it is performed as part of the
standard of care for lung cancer. Additionally, because of its non-invasive nature, CT
imaging can be used to achieve high temporal resolution via frequent imaging (17). CT
imaging also has high spatial resolution which can allow for quantification and assessment of
intra-tumor spatial heterogeneity (17). This is important since identification of an image
heterogeneity – treatment response link could be used to further optimize the therapeutic
ratio of radiation treatments (18).
Various CT image features can be useful descriptors. In NSCLC, tumors are often
qualitatively described as spiculated or cavitated, and several groups are working to develop
a constrained vocabulary for lung tumor CT image annotation (19, 20). Tumors are also
commonly described by quantitative one-dimensional (Response Evaluation Criteria in Solid
2

Tumors) or two-dimensional (World Health Organization) size measurements. However, the
nuances of tumor morphology are not well-captured by these two measures, and in some
cases their changes do no strongly correlate with therapeutic benefit (21, 22). Other
commonly obtained quantitative image features such as the mean voxel intensity are
typically simple calculations over the region of interest (ROI) (23). More advanced
quantitative measures are usually statistical, model, or transform based and reflect variations
in tumor morphology, heterogeneity, and/or texture (24). Statistics-based image features
such as the run-length matrix (RLM) and co-occurrence matrix (COM) are based on
probabilities of voxels occurring in certain combinations (25, 26). Model-based image
features such as the fractal dimension quantify texture irregularity and roughness (24).
Transform-based methods such as the wavelet transform are used to quantify textures in the
frequency space (24). Compared to simple ROI-averaged image features, these more
advanced features tend to have significantly improved prognostic power (27-30).
Inspired by the high-throughput success of the “omics” (genomics, proteomics,
metabolomics, etc.), the newly created field of radiomics is centered around the highthroughput extraction of advanced quantitative image features (17). The radiomics
hypothesis is that these image features are related to a tumor’s underlying genotype and
phenotype. This was first shown to be true in liver cancer where 28 image features were
able to reconstruct 78% of the gene expression profile (31). Other studies have shown that
genomic heterogeneity, treatment resistance, and metastatic probability are each associated
with tumor image heterogeneity (27, 32). In addition, CT texture analysis can indicate tumor
invasion and estrogen receptor status in patients with breast cancer, can partition high and
low grade cerebral gliomas, and can indicate overall survival rates in colorectal cancer (3335). In lung cancer, image features have also been used to distinguish between the
adenocarcinoma and squamous cell carcinoma subtypes of NSCLC (36). The fractal
dimension of lung tumors has been used to classify pulmonary nodules and also correlates
with tumor stage (37, 38). NSCLC CT texture analysis by Ganeshan et al. has also
3

discovered image feature associations for tumor stage, metabolism, hypoxia, and
angiogenesis (39, 40).
Particularly in NSCLC CT radiomics applications, authors often lament the lack of
data standardization and uniformity (41). This is an important point to consider, because
NSCLC radiomics models could be easily confounded by patient variability (different
treatment types, different disease stages, different demographics, etc.), image variability
(motion management, voxel size, contrast vs. no contrast, helical vs. axial, etc.), or by
interpretation variability (inter-operator segmentation differences, subtle differences in image
feature extraction algorithms, etc.). Each of these sources of variability needs to be carefully
minimized. In theory, interpretation variability can be controlled for through automated
segmentation and feature extraction standardization. Patient variability, on the other hand,
cannot be controlled for on data sets studied retrospectively. This is a challenge because
training a model requires as many patient-outcome pairs as possible and this is usually at
odds with patient uniformity. Image variability also introduces the same problem: obtaining a
larger sample to study introduces more variability.
To address some of these concerns, the Quantitative Imaging Biomarkers Alliance,
organized by the Radiological Society of North America in 2007, is working to harmonize
imaging standards across institutions and CT machine venders (42). Additionally, in a simple
water phantom study, several CT texture features have been shown to be relatively robust to
kVp and mAs variation (43). For more complex human data, there is a publically available
“test-retest” dataset of 32 NSCLC patients in which each patient was scanned twice on the
same CT machine with a short break in between (44). This dataset was utilized by Kumar et
al. (23) to identify 39 out of 327 image features that were reproducible, non-redundant, and
informative. Reproducibility was quantified by the concordance correlation coefficient (45)
and is desirable to ensure imaging biomarker model fidelity and generality. Informativeness
was quantified using the dynamic range and is important for discerning patients. Non-
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redundance was quantified by feature correlation coefficients and is desirable to increase
model interpretability and reduce overfitting.
Basu et al. (2012) extracted these 39 features from a separate set of 95 NSCLC
patients, binarized patient outcomes around 2 year survival, and tested various classifiers to
obtain an area under the curve (AUC) of 0.68 (41). However, this study is limited by
treatment variability and imaging variability within its patient dataset. Patients received
different types of radiation treatments and chemotherapy, and imaging was done on several
different machines with considerable parameter variation. For example, slice thickness was
highly variable for the images and likely limited the usefulness of RLM and COM features
since they assume a static voxel size. Aerts et al. (2012) performed a similar survival
prediction study on a larger data set (412 patients) and obtained an AUC of 0.70 (46, 47).
Besides being limited by treatment variability and imaging variability, these two studies
assumed that the reproducible feature set found by Kumar et al. (23) would also be
reproducible on the machines used to collect their data, but the validity of this assumption is
unclear. Therefore, to expand upon previous work in NSCLC CT radiomics, the significance
of this project is to 1) predict NSCLC treatment outcome from patients with uniform treatment
and imaging and 2) use public and internal NSCLC CT test-retest datasets to identify image
features that are robust across multiple CT machines.
1.2 Hypotheses
1. CT image features extracted from pre-treatment NSCLC tumors can be used to
predict tumor shrinkage in response to therapy.
2. Using several selection metrics, a small subset of multi-machine reproducible,
non-redundant, and informative image features can be identified for each of
several different CT image types.
1.3 Specific Aims
The hypotheses will be tested through the following specific aims:
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1. Develop MATLAB code which can access ROIs from the Pinnacle3 TPS and extract
3D quantitative image features from an ROI’s geometry, intensity histogram, absolute
gradient image, run-length matrices, and co-occurrence matrices.
2. Predict NSCLC tumor shrinkage for patients treated with IMRT and PSPT using
models based on pre-treatment CT image features.
3. Develop a user-friendly graphical user interface program to leverage previously
developed code by streamlining Pinnacle ROI location, verification, and image
feature extraction.
4. Characterize the reproducibility, non-redundance, and informativeness of CT image
features and identify subsets of image features that are optimal under image
acquisition protocols.
1.4 Thesis Organization
This thesis is intended to serve as a permanent record of the work that was
completed to evaluate the hypotheses of the project. Chapters 2 and 3 are self-contained
studies, each including an introduction, methods, results, discussion, and conclusions.
These chapters each describe separate portions of the work completed for this project.
Chapter 2 addresses specific aims 1 and 2, providing reasonably accurate
predictions of NSCLC tumor shrinkage from pre-treatment CT images. Chapter 3 addresses
specific aims 3 and 4, and lists relatively small image feature sets that are reproducible, nonredundant, and informative for each of the following image types: cine 4D-CT average
images, cine 4D-CT end-exhale images, and inspiratory breath-hold helical 3D-CT images.
In closing, Chapter 4 is a summary of the overall research project. This section assesses the
hypotheses, draws overall conclusions, and proposes future related research.
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Chapter 2: NSCLC tumor shrinkage prediction using quantitative image features
2.1 Introduction
A goal of oncology therapies is to utilize information gained from treating previous
patients to deliver treatment specific to the patient and disease. The current tumor node
metastasis (TNM) staging system for non-small cell lung cancer (NSCLC) is used for this
purpose and utilizes anatomical information such as the tumor size, location, spread, and
lymph node involvement (6). Although this system is based on the study of over 67,000
NSCLC cases, NSCLC patients with the same TNM staging often have very different clinical
outcomes. To improve this, many models have been proposed which add additional nonanatomical features to the TNM staging system. For example, the readily available features
of age and body mass index have been shown to improve NSCLC staging (8). Others have
used single nucleotide polymorphism genotyping to predict survival (9-11). NSCLC
recurrence prediction from serum biomarkers has also been explored (12). However, these
molecular assays are invasive, much less commonly obtained than age and body mass
index, and could be sensitive to variations in institution demographics, sample collection,
and/or analysis techniques. Moreover, molecular assays are also limited by the fact that
many tumors are spatially and/or temporally heterogeneous (48, 49).
CT images, on the other hand, are ubiquitous, non-invasive, and increasingly
quantitative and standardized. They can also assess the tumor both spatially and through
time (48). In basic quantitative CT imaging, such as the Response Evaluation Criteria in
Solid Tumors (RECIST) guidelines, tumor response to therapy is gauged by onedimensional measurements of tumor size (50, 51). However, using more complex
quantifiable image features such as the tumor heterogeneity and radiodensity can result in a
significant prognostic improvement over RECIST (22). Other quantitative image features are
usually statistical, model, or transform based and show similar prognostic promise (24, 2730). In light of these findings, the nascent field of radiomics aims to achieve automated highthroughput extraction of various quantitative image features under the hypothesis that they
7

are related to gene expression and phenotype. Supporting this claim, Segal et al. (2007)
showed that 28 image features could reconstruct 78% of a liver cancer gene expression
profile (31). Additionally, it has been demonstrated that features such as the tumor image
heterogeneity are associated with genomic heterogeneity and are correlated with increased
treatment resistance and metastatic probability (27, 32).
Recently, radiomics has been applied to NSCLC survival prediction. Kumar et al.
(2012) extracted 327 3D features for 32 patients who underwent two CT imaging sessions
spaced 15 minutes apart on the same machine (52). To assess intra-patient (test-retest)
reproducibility, they calculated feature concordance correlation coefficients and dynamic
ranges and determined that 39 of these 327 features were highly reproducible. Using this
information, Basu et al. (2012) extracted these 39 features from a separate set of 95 NSCLC
patients, binarized patient outcomes around 2 year survival, and tested various classifiers to
obtain an area under the curve (AUC) of 0.68 (41). Aerts et al. (2012) used similar
techniques on a larger data set (412 patients) to obtain an AUC of 0.70 (46, 47).
There are several limitations to these studies, however. First, both used multiple CT
machines to establish their CT data sets. At our institution we have found that quantitative
image features vary significantly across different machines, even of the same model. Given
the large size of the databases used in these two studies, it is likely that several machines
were used and it is possible that their prognostic power was limited by inter-machine
variability. Moreover, inter-machine variability could also affect the intra-patient variability. It
is not clear that the same set of features identified by Kumar et al. (52) would be
reproducible on other machines as was assumed by Basu et al. (41). Finally, both the work
by Basu et al. (41) and Aerts et al. (46) have inter-patient treatment variability which could
similarly limit the prognostic power of their models.
In summary, although increasing patient database size is desirable to provide
enough training inputs to create models with sufficient expressiveness, it may be
counterproductive if it results in increased image and/or treatment heterogeneity that
8

confounds modelling. Therefore, the purpose of our study was to develop a quantitative
image feature-derived prediction model for NSCLC volume shrinkage (a proxy for survival)
on a set of patients with similar treatments all imaged with the same CT scanner and
protocol.
2.1 Materials and methods
Data acquisition
We obtained simulation and weekly free-breathing, non-contrast 4DCT images from
66 patients with locally advanced, pathologically proven stage II-IIIB NSCLC. As part of a
separate prospective trial comparing treatment modalities, these patients were randomly
assigned treatment either by IMRT (36 patients) or protons (30 patients). The protons were
delivered with passively scattered proton therapy with an assumed relative biological
effectiveness (RBE) of 1.1. Both groups were treated to a 74 Gy (RBE) dose level and had
concurrent chemotherapy. All simulation images were acquired with the same GE Medical
Systems LightSpeed 16 machine (GE Healthcare, Milwaukee, WI) with helical scans using
kVp = 120, mAs = 450, and a standard reconstruction convolution kernel. Axial images were
512 x 512 pixels with voxel dimensions of 0.98 x 0.98 x 2.5 mm3.
To minimize the effects of respiratory motion, physicians contoured the gross tumor
volumes (GTVs) on the end-exhale (T50) phase of planning 4DCT images. These contours
were propagated onto weekly images using an in-house demons-based deformation
algorithm (53, 54). For each patient, the weekly GTV volume divided by the planning GTV
volume was defined as the tumor response for a particular week.
Although both treatment regimens lasted longer than six weeks, for logistical reasons
some patients did not have 4DCT scans after week six. Therefore, week six was chosen as
the “final” time point for prediction of the tumor response from the initial planning images. For
modelling, both the IMRT and proton data sets were pooled in order to obtain a larger set of
observations, and one patient from each group was thrown out for being a tumor response
outlier (deviating by more than two standard deviations). Results from (55) support pooling
9

the two data sets by showing that each group had remarkably similar tumor responses (see
Table 2.1). In fact, the p-value that the two groups’ tumor responses have equal means is
0.733.
Table 2.1: Week six tumor responses by treatment modality. The weekly tumor
response is defined as the GTV volume for the week divided by the GTV volume on
the planning image. Intensity modulated radiation therapy (IMRT) and passively
scatted proton therapy (PSPT) patients showed remarkably similar tumor responses
and were pooled for the purpose of modelling.
Treatment
Std.
Group

N

Mean

Median

Max

Min

Dev.
IMRT

36

0.83

0.85

0.19

1.39

0.47

PSPT

30

0.81

0.81

0.19

1.45

0.46

IMRT+PSPT

66

0.82

0.82

0.19

1.45

0.46

Feature extraction
We extracted quantitative image features from the pre-treatment planning GTVs
using in-house software that used the following 3D feature sources: geometry, intensity
histogram, absolute gradient image, co-occurrence matrix (COM), and run-length matrix
(RLM). See Table 2.2 for a complete listing of features extracted from each feature source.
For the absolute gradient image, each voxel is defined as the difference between paired
adjacent voxels in all three directions added in quadrature. For a given image and direction,
the run-length matrix  ,
and run length

is defined as the number of voxel runs in the image with intensity

(26). RLM features were extracted for 13 different 3D directions. For a

, a co-occurrence matrix  ,
given image and displacement vector ∆

is defined as the

 will have the intensity values of
probability that two voxels separated by ∆

and ,

respectively (25). COM features were extracted for six different one-voxel displacements:
left, right, superior, inferior, anterior, and posterior.
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Table 2.2: List of quantitative image features extracted from each planning CT image
GTV. The RLM features were generated for 13 different 3D directions, and the COM
features were generated for 6 different 3D displacements.
Intensity

Absolute

Run-Length

Co-Occurrence

Geometry

Histogram

Gradient

Matrix (RLM)

Matrix (COM)

Volume (V)

Mean

Mean

Run Length Nonuniformity

Angular 2nd Moment

Area (A)

Median

Variance

Grey Level Nonuniformity

Contrast

V/A Ratio

Variance

Skewness

Long Run Emphasis

Correlation

Pruned Volume

Skewness

Kurtosis

Short Run Emphasis

Sum of Squares

Pruned Area

Kurtosis

% Non-Zero

Fx. of Image in Runs

Inv. Diff. Moment

Pruned V/A Ratio

Minimum

Sum Average

Fx. Volume Pruned

1th percentile

Sum Variance

10th percentile

Sum Entropy

th

90 percentile

Entropy

99th percentile

Diff. Variance

Maximum

Diff. Entropy

Entropy

Prior to feature extraction, we pre-processed the GTV regions of interest (ROIs) by
pruning (removing voxels below a certain Hounsfield unit [HU] cut-off). This was done to
reduce contouring variability, remove air cavities, and better define the solid tumor. However,
the optimal HU cut-off was not known a priori, so each unprocessed ROI gave rise to several
variants, each of which had different HU cut-offs. Because the optimal voxel intensity bit
depths were also unknown, each of these variants then gave rise to additional variants for
which the gradient, RLM, and COM image bit depths were varied. Thus, for each patient’s
ROI, many additional ROIs with different pruning and bit depths were created. Figure 2.1
illustrates this process. For each unique HU cut-off and bit depth combination, the resulting
ROIs were pooled from the 64 patients and features were extracted to create a feature
matrix with each row corresponding to a patient and each column corresponding to a
feature.
11

Figure 2.1: Region of interest (ROI) pre-processing. For each patient, the ROI was
extracted according to physician-generated contours. Multiple pruned variants of
these ROIs were created by removing voxels below various HU cut-offs. From each of
these variants, additional variants were created and saved using several different bit
depths (BD).
We define a feature set as a collection of feature matrices where each feature matrix
within the feature set was generated using a unique set of extraction parameters (e.g. HU
cutoff and bit depths). To investigate the predictive power of various feature sources, we
created four feature sets. Each of of the four feature sets used different feature sources and
feature extraction parameters as indicated by Table 2.3.
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Table 2.3: Feature set feature sources and extraction parameters. The feature set
column denotes the name of a feature set as well as the source of features used to
create the feature matrices that it contains (GEO = geometry, INT = intensity
histogram, GRAD = absolute gradient image). The feature extraction parameter
column shows the different feature extraction parameters that were used for each
feature set (HU = Hounsfield unit, BD = bit depth). To populate the associated feature
set, a feature matrix was generated for each unique combination.
Feature Set
Feature Extraction Parameters
GEO + COM

HUcutoff = -250, -200, -150, -100, -50
BDCOM = 5, 6, 7, 8, 9

GEO + RLM

HUcutoff = -250, -200, -150, -100, -50
BDRLM = 5, 6, 7, 8, 9

GEO + INT + GRAD

HUcutoff = -250, -225, -200,-175, -150, -125, -100, -75, -50
BDGRAD = 4, 5, 6, 7, 8
HUcutoff = -250, -200, -150, -100, -50
BDCOM = 5, 6, 7

ALL

BDRLM = 5, 6, 7
BDGRAD = 5, 6, 7

Modelling
The fitness of prediction models was quantified using the mean squared error (MSE)
between predictions and observations. The method for obtaining the MSE of a feature matrix
 with column selection vector  using leave-one-out cross-validation is described here and
in Figure 2.2. First, a row is omitted from a feature matrix and the remaining training
observations are projected into z-score space. These are then projected into principal
component (PC) space. Dimensionality reduction is achieved by removing PC dimensions
that have trivial components for all training observations. Next, multiple linear regression is
performed using the PC space columns indicated by the Boolean vector . Tumor responses
are used as the regression target. The resulting model is known as the principal component
regression (PCR) model (56).
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Finally, the omitted row is converted into the same z-score PC space as the training
observations and fed into the PCR model in order to obtain a tumor response prediction for
the hidden observation. The squared difference between the predicted and observed tumor
response is recorded. This process is repeated for each row to obtain the leave-one-out
cross-validation MSE.
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Figure 2.2: Principal component regression with leave-one-out cross-validation; the
method for obtaining the mean squared error (MSE) of a feature matrix  with column
 using leave-one-out cross-validation.
selection vector 
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Optimization
The previous section described how to obtain MSE as a function of the feature matrix
and the column selection vector (i.e. ,  ). This section will describe how the simulated
annealing principal component regression (SA-PCR) technique was used to find the  and 
which give the best ,  . First, a feature set from Table 2.3 was selected. For each
feature matrix  in this feature set, a simulated annealing process (57) is performed using a
geometric cooling function with   1  10 and   1  10 . The Boolean vector  is
randomly initialized and then allowed to evolve according to the simulated annealing process
through  = 1,000 steps using ,  as the objective function.
Out of all of the feature matrices in the feature set, the  and  that give the lowest
MSE are taken to be the best  and . Since each feature matrix is generated by a unique
set of feature extraction parameters, the best  then implies the best feature extraction
parameters (i.e. HU cut-off and bit depths). The best  indicates which dimensions of the
feature z-score PC space are best for multiple linear regression modeling. Together the best
 and  define the best model.
Because simulated annealing is stochastic, for the same input feature set the SAPCR algorithm may return different best MSEs for each execution. Therefore, in order to test
the stability of the results, we repeated the entire SA-PCR process 100 times for each
feature set in Table 2.3.
Validation
Even though the SA-PCR process implements leave-one-out cross-validation,
because it considers many feature matrices and many feature z-score PC space selection
vectors, there is a possibility that the best MSE and associated  and  that it finds are due
to coincidence or spurious correlations. To test for this possibility, we performed a negative
control study. We again performed the entire SA-PCR process 100 times for each feature
16

set in Table 2.3 as was done to study the stability of the SA-PCR results. However, in this
case, for each run the tumor response vector was randomly permuted with respect to the
associated feature matrix (independently for each run). This obliterated any prognostic
relationship between the feature matrix and the tumor response vector.
2.3 Results
Algorithm stability
The histogram bins in Figure 2.3 indicate the number of times out of 100 runs that the
best MSE returned by the SA-PCR algorithm fell into the indicated MSE range using the
specified feature set.

The Experiment bars indicate the stability test results where the

feature matrices are correctly paired with the tumor response vector. The dispersion of these
distributions can be quantified using the coefficient of variation (CV). The GEO+COM feature
set had

!"#$  3.77  10, the GEO+RLM feature set had

GEO+INT+GRAD feature set had

!"#$  2.32  10, the

!"#$  4.98  10, and the ALL feature set had

!"#$  6.01  10.
These small coefficients of variation indicate that the SA-PCR algorithm is stable and
returns similar MSEs for the same input, despite being a stochastic algorithm. Thus, if the
SA-PCR algorithm was deployed as a part of a clinical workflow, 100 repetitions would not
be needed in order to generate a good prediction model. A single run would suffice and
would take approximately 18 minutes on a single core machine but is easily parallelizable
and runs in about 1.5 minutes on our 12 core machine.
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Figure 2.3: SA-PCR algorithm stability and validation. Histogram bins indicate the
number of times out of 100 runs that the best MSE returned by the SA-PCR algorithm
fell into the indicated MSE range using either a) geometric and COM features, b)
geometric and RLM features, c) geometric, intensity histogram, and gradient features,
or d) using all features (geometric, intensity histogram, gradient, RLM, and COM).
Experiment indicates that the tumor response vector was correctly ordered with
respect to the feature matrix. Negative control indicates that the tumor response
vector was randomly permuted with respect to the feature matrix (independently for
each run).
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Algorithm validation
The Negative Control bars in Figure 2.3 indicate the negative control results when
the feature matrices are paired with independently randomly permuted tumor response
vectors. These negative control MSE distributions are well separated from the experiment
distributions for the GEO+INT+GRAD and ALL feature sets. However, there is an overlap
between the experiment and negative control distributions for the GEO+COM and
GEO+RLM feature sets. The probability of an experiment MSE being due to spurious
correlation can be approximated by calculating the one-sided p-value of the mean MSE
returned by experiment runs given negative control distribution. Using a normal
approximation for the negative control distributions gives   1.09  10+

for the

GEO+COM feature set,   4.87  10+ for the GEO+RLM feature set,   4.36  10, for
the GEO+INT+GRAD feature set, and   5.02  10 for the ALL feature set.
If the “good” MSEs found by the SA-PCR stability tests were due to spurious
correlations, then the negative control runs should generate similarly “good” MSEs or even
better MSEs (some tumor response vector permutations may be more susceptible to
spurious correlations). However, this is not what was observed. Figure 2.3 shows that the
SA-PCR stability test MSEs are significantly and systematically lower than the negative
control MSEs (p-values estimated above). This indicates that there is a valid prognostic
relationship between the feature matrix and the tumor response vector that is not due to
spurious correlations within the data.
Algorithm Findings
For each of the four feature sets listed in Table 2.3, the best  and  (i.e. the best
model) was found using 100 repetitions of the SA-PCR method. Figure 2.4 shows these
results graphically. The best model predictions from each feature set are displayed with the
observed tumor response on the x-axis versus the leave-one-out predicted tumor response
on the y-axis. Table 2.4 displays the optimal feature extraction parameters found for each
feature set. The overall best model was found using the ALL feature set with a Hounsfield
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unit cut-off of .250 and bit depths of 5 for the RLM, 7 for the COM, and 5 for the absolute
gradient image.

Figure 2.4: Model predictions. Each panel plots the observed tumor responses vs. the
leave-one-out tumor response predictions from the best model found in 100 runs of
the SA-PCR algorithm operating on one of the following feature sets: a) geometric and
COM features, b) geometric and RLM features, c) geometric, intensity histogram, and
gradient features, and d) all features. Note: tumor response = the final GTV volume
(GTVf) divided by the initial GTV volume (GTVi); the MSE and Pearson’s r value are
indicated for each panel; a line with slope = 1 (i.e. perfect prediction) is shown as a
reference.
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Table 2.4: Optimal feature extraction parameters. A bit depth of 12 was used for all
intensity histogram derived features.
HUcutof
BDRLM BDCOM BDGRAD BDINT
Feature Set
f

GEO + COM

-250

-

7

-

12

GEO + RLM

-250

5

-

-

12

GEO + INT + GRAD

-225

-

-

5

12

ALL

-250

5

7

5

12

To put the MSE values of Figure 2.4 in context, the best model found using the ALL
feature set is shown in Figure 2.5 alongside two alternative prediction models. Figure 2.5b
shows the predictions of the simplistic mean model where the “left out” patient is predicted to
have a tumor response equal to the mean of all of the observed tumor responses. This gives
an MSE of 2.51  10 which is 2.92 times larger than the best MSE found by the SA-PCR
algorithm on the ALL feature set (Figure 2.5a). The negative control model shown in Figure
2.5c was generated from the ALL feature set using a random permutation of the tumor
response vector. Without the true feature-response (input-output) pairings, this model is
unable to produce a linear trend and instead clusters predictions around the mean tumor
response

value.
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Figure 2.5: Comparison between tumor response models. Panels show the observed
tumor response vs. leave-one-out tumor response predictions from a) the optimal SAPCR model using the ALL feature set, b) the mean model (i.e. predicted response =
mean response), and c) an SA-PCR model using the ALL feature set with a random
permutation of the tumor responses with respect to the feature matrix.
For each leave-one-out cross-validation step illustrated in Figure 2.2, PCR generates
regression coefficients for each of the principal components indicated by . By averaging
these coefficients across all cross-validations, the coefficient with the largest average
absolute value can be identified. The principal component associated with this coefficient is
then the most dominant principal component for determining the prediction. Figure 2.6
shows the projection of such a dominant principal component into the feature z-score space
for the best model found using the ALL feature set. From this projection it is clear that no
particular image feature dominates the dominant principal component. That is, no single
image feature seems to be a strong tumor response predictor; rather, it appears that the
interaction of multiple features gives rise to the best model.
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Figure 2.6: Projection of the dominant principal component into the original image
feature z-score space for the best model found using the ALL feature set.

2.4 Discussion
Tumor response as a prediction outcome
When deciding treatment options, predicting patient outcome regarding survival and
normal tissue toxicity is paramount. However, as our patients are currently part of an
ongoing study these data are not yet available. Therefore, tumor response was used as a
substitute. We believe that tumor response (i.e. tumor shrinkage) is an acceptable proxy for
patient outcome due to the current RECIST guidelines which state:

“The use of tumor regression as the endpoint for phase II trials… is supported by
years of evidence suggesting that… tumor shrinkage… demonstrates an
improvement in overall survival or other time to event measures in randomized phase
III studies.” (58)

When the data is available, we plan to determine the ability of quantitative image
feature models to predict normal tissue complications and survival.
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Pooling photon and proton patients
Although the photon and proton patients technically received different treatments, we
believe that for the outcome of tumor response they can be approximated as receiving the
same treatment. This can be justified from a theoretical standpoint since the GTVs of each
modality were planned to receive exactly the same RBE-adjusted dose, and this argument is
supported by the empirical findings of (55) (see Table 2.1).
As per the study’s design, the only dosimetric difference between the two treatment
groups is for normal tissue dose. Thus, in the future, for the outcome of patient survival,
there may be differences between the two groups arising from differences in normal tissue
dose between the two treatment modalities. In such a scenario, pooling the two patient
groups would not be appropriate for prediction of the alternative outcome of survival.
Principal component regression as a model choice
Inspection of the image feature covariance matrices showed that many features were
highly correlated. This can make standard multiple linear regression unreliable because
small changes in the data can cause large, erratic changes in the estimated coefficients.
This is known as the problem of multicolinearity (59). By creating a basis space of
orthogonal principal component vectors, PCR is a way to address this problem and also
provides dimensionality reduction. However, (60) has shown that the principal components
with the most variation are not always optimal for modelling. Thus, we introduced the
simulated annealing algorithm as a method to find which principal components should be
included for modelling.
Reproducibility and robustness against spurious correlation
The low coefficients of variation for the experiment distributions of Figure 2.3
demonstrate the reproducibility of the SA-PCR algorithm on our dataset. Absent or minimal
overlap between the experiment and negative control distributions in Figure 2.3 also
demonstrate robustness to spurious correlations. With a p-value of 4.36  10, for the
separation between its experiment and negative control distributions, the GEO+INT+GRAD
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feature set results are the least likely to be due to spurious correlation. This implies that in
cases where there are few patient observations, it may prudent to omit RLM and COM
features for model construction and only use geometric, intensity histogram, and absolute
image gradient features. Although this may slightly decrease the MSE compared to using all
features, it will give a better guarantee that the model found truthfully identifies a relationship
between the image features and the tumor shrinkage. Omitting the RLM and COM features
would also make the parameter space easier to search since RLM and COM bit depths are
no longer required.
The optimal feature extraction parameters shown in Table 2.4 indicate that the
optimal bit depth for each feature source (e.g. RLM, COM, etc.) appears to be independent
of the other bit depths. That is, the optimal RLM bit depth found with the GEO+RLM feature
set was the same as the optimal RLM bit depth found using the ALL feature set. This was
also true for the COM and absolute gradient image bit depths. Thus, in the future it may be
prudent to search for each optimal bit depth individually and then combine them when a
model using all features is desired. As for the optimal HU cut-off, it appears to be
approximately the same for each feature set and is always at or near the lowest HU cut-off
that was explored. This indicates that future studies should consider lower HU cut-offs and
also hints that the air-tissue boundary may contain important prognostic information
(otherwise the optimal HU cut-offs would have been higher).
Model success and applicability
Our findings indicate that a quantitative image feature model can use existing CT
images to successfully predict tumor shrinkage (see Figure 2.4). In fact, Figure 2.5 shows
that, relative to the simplistic mean model, the tumor shrinkage uncertainty can be reduced
by nearly a factor of three. This is very important because tumor shrinkage is prognostic, and
thus our predictions are also prognostic. For example, a patient predicted to have a poor
response to a particular treatment can be identified before the treatment begins. From here
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he can either be labelled as high risk and watched closely or perhaps be transferred to a
different treatment strategy.
At the present, however, it is not known whether or not the models developed in this
study can be applied to similar patients at other institutions. The model could be invalidated
by different treatments, different imaging, and/or different patient demographics. We suggest
a group of institutions work together to perform a study similar to (52) across multiple CT
scanners to identify robust quantitative image features. Once these features are identified,
standardized treatments and demographics could be agreed on, and robust predictive
models for patient outcomes could be explored.
2.5 Conclusion
Quantitative image feature models derived from existing pre-treatment CT images
were successfully able to predict NSCLC tumor shrinkage, an indicator of treatment efficacy
and future survival. This supports the findings of (41) and (46) which showed that binary
classifiers operating on quantitative image features could be used to predict survival
outcomes for patients with NSCLC. When survival data is available for our patients we will
develop similar classifiers and compare AUCs to their findings. Since our cohort’s imaging
and treatment are both relatively homogenous compared to these studies, such future work
could indicate how much imaging and treatment heterogeneity can affect the prognostic
power of quantitative image feature models.
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Chapter 3: Identification of multi-machine reproducible and non-redundant NSCLC CT
image features
3.1 Introduction
In computed tomography (CT) imaging, non-small cell lung cancer (NSCLC) tumors
are often described using qualitative descriptors (spiculated, cavitated, heterogeneous,
etc.)(61, 62). However, recently there has been a move towards generating additional
quantitative, objective features to describe these tumors (17). Traditional quantitative
measures have included the one-dimensional tumor size, mean voxel intensity, intensity
standard deviation, etc. (50, 58, 63). Newer quantitative measures are usually statistical,
model, or transform based and reflect variations in tumor morphology, heterogeneity, and/or
texture (24). Motivated by the hypothesis that these quantitative image features are related
to gene expression and phenotype, the field of radiomics aims to achieve their automated,
high-throughput extraction from standard of care images (23). Ganeshan et al. have shown
that quantitative measures of NSCLC CT heterogeneity are associated with tumor stage,
metabolism (39), hypoxia, and angiogenesis (40). Other quantitative image features have
been applied to classify NSCLC as adenocarcinoma or squamous cell carcinoma (36), and
lung tumor image fractal dimension has been shown to correlate with tumor stage (38) and
can classify pulmonary nodules (37). Thus, several lines of evidence support the radiomics
hypothesis for NSCLC.
For NSCLC radiomics to be applied clinically, the intra- and inter-machine
reproducibility of image features must be addressed. Towards this goal, the Quantitative
Imaging Biomarker Alliance has created a technical committee dedicated towards multivender CT scan standardization for the measurement of lung nodules (42). In a CT phantom,
Ganeshan et al. (43) showed that quantitative measures of entropy and uniformity have
lower coefficient of variation values than the mean intensity. For human study, public data is
available from 32 NSCLC patients each scanned twice (15 minutes apart) using the same
CT machine and protocols (44) (Figure 3.1). Kumar et al. (23) recently used this so-called
27

“test-retest” dataset to identify 39 out of 327 image features that were reproducible,
informative, and non-redundant.
The purpose of our study is to expand upon the work of Kumar et al. (23) by adding
test-retest datasets from additional machines and image types. By studying different image
types (cine 4D-CT end-exhale phase vs. average cine 4D-CT vs. breath-hold helical 3D-CT)
we can determine which image type will give the most reproducible image features. By
studying different machines we can investigate how much machine variation affects
reproducibility. We also propose a way to integrate reproducibility and redundancy findings
across multiple machines to identify a cross-machine reproducible and non-redundant image
feature set. This robust set of NSCLC image features could be useful for the development
and validation of multi-machine and multi-institutional NSCLC radiomics models.

Figure 3.1: Publically available test-retest images taken 15 minutes apart.

Materials and methods
Test-retest datasets
We obtained non-contrast-enhanced cine 4D-CT test-retest scans from 31 patients
with NSCLC who were imaged at the University of Texas M.D. Anderson (MDA) Cancer
Center in Houston, TX (64). 16 of these test-retest pairs were acquired on a GE (General
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Electric Healthcare, Milwaukee, WI) Discovery ST model machine (“M1”) and 15 were
acquired on a GE LightSpeed RT 16 model machine (“M2”). Imaging parameters are shown
in Table 3.1. We also obtained breath-hold, non-contrast-enhanced helical 3D-CT test-retest
scans from 25 patients with NSCLC who were imaged at the Memorial Sloan-Kettering
Cancer Center in New York, NY (65). This is the dataset used by Kumar et al.(23) and is
publically available as part of the Reference Image Database to Evaluate Therapy Response
(RIDER) (44) collection hosted by the Cancer Imaging Archive (TCIA) at Washington
University in Saint Louis, MO.
The complete RIDER dataset has 32 test-retest patients and was collected with two
machines: a GE LightSpeed 16 and a GE LightSpeed VCT 64. However, to isolate machine
variation we omitted test-retest pairs from the GE LightSpeed VCT 64 machine; we also
removed scans with GTVs that had image artifacts or appeared too difficult to contour
accurately. This resulted in 25 test-retest pairs all acquired on the same machine, a GE
LightSpeed 16 (“M3”). These scans had variable axial pixel dimensions because the field of
view was independently set for each scan based on its scout image. Therefore, a “virtual”
fourth machine (“M4”) was created by taking each M3 scan and performing 3D cubic spline
interpolation to generate a new scan with the same voxel size as the MDA images. This was
done to test if features could be extracted more reproducibly from scans with a uniform voxel
size.
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Table 3.1: CT machine parameters. MDACC indicates M.D. Anderson Cancer Center;
MSKCC, Memorial Sloan-Kettering Cancer Center.
Machines
Parameter

M1

M2

M3

Test-Retest Pairs

16

15

25

Institution

MDACC

MDACC

MSKCC

GE Machine Model

Discovery ST

LightSpeed RT 16

LightSpeed 16

Detector Rows

8

16

16

Scan Mode

Cine 4D

Cine 4D

Helical 3D

Breathing

Free

Free

Insp. hold

kVp

120

120

120

Exposure Time (ms)

500

500

493 ± 42

Tube Current (mA)

100

200

339 ± 63

Filter Type

BODY

BODY

BODY

Convolution Kernel

STANDARD

STANDARD

LUNG

Axial Pixel Size (mm)

0.98

0.98

0.68 ± 0.10

Slice Thickness (mm)

2.5

2.5

1.25

Focal Spot Size (cm)

0.7

0.7

1.2

Feature Extraction
To minimize inter-operator contour variation, a single operator (the primary author)
was responsible for contouring the 174 GTVs used in our study. All contouring was
performed with the Pinnacle3 TPS (treatment planning system; Philips Medical Systems,
Andover, MA) using its slice by slice auto-contour function with a lower bound of 0 and an
upper bound of 500 (values selected to increase automation and reproducibility). For 4D-CT
scans, GTVs were contoured on the T50 phase (end-exhale) images and the average (AVG)
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images. Clinical treatment plans with physician-generated GTVs were used to identify lesion
locations. For the 3D-CT scans, lesions were located and contoured using dataset
annotations from the TCIA website. In the interpolated dataset, the binary mask from original
voxel size scans underwent a 3D cubic spline interpolation and thresholding to determine the
new GTV mask.
For quantitative image feature extraction, we developed the in-house Imaging
Biomarker Extractor (IBEX) software package.

IBEX was developed using MATLAB

(Mathworks Inc., Natick, MA) and has a graphical user interface which can directly access
images and regions of interest (ROIs) from the Pinnacle3 TPS file system. Using this
information, it can extract image features from the following 3D feature sources: geometry,
intensity histogram, absolute gradient image, co-occurrence matrix (COM) (25), and runlength matrix (RLM) (26).

For a complete list of features extracted, refer to Table 3.2.

Additionally, for NSCLC GTVs it is common to remove voxels from the GTV region of
interest that are below a certain Hounsfield unit (HU) cutoff before performing feature
extraction (39, 40). This is thought to refine the ROI, making it more reproducible and
focusing feature extraction on tissues other than air. IBEX allows for the specification of an
HU cutoff to support this capability.
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Table 3.2: Image Features Extracted with the Imaging Biomarker Extractor (IBEX)
Software.
Intensity

Absolute

Run-Length

Co-Occurrence

Geometry

Histogram

Gradient

Matrix (RLM)

Matrix (COM)

Volume (V)

Mean

Mean

Run Length Nonuniformity

Angular 2nd Moment

Area (A)

Median

Variance

Grey Level Nonuniformity

Contrast

V/A Ratio

Variance

Skewness

Long Run Emphasis

Correlation

Pruned Volume

Skewness

Kurtosis

Short Run Emphasis

Sum of Squares

Pruned Area

Kurtosis

% Non-Zero

Fx. of Image in Runs

Inv. Diff. Moment

Pruned V/A Ratio

Minimum

Fx. Volume Pruned

Sum Average

th

1 percentile

Sum Variance

10th percentile

Sum Entropy

th

90 percentile

Entropy

99th percentile

Diff. Variance

Maximum

Diff. Entropy

Entropy

In our analysis, we used IBEX to extract image features from each GTV using the
four 3D sources described. RLM features were extracted for 13 different 3D directions, and
COM features were extracted for 3 different 3D displacements. For many features, the
resulting values can vary substantially depending on the bit depth used to represent the
image. Therefore, in order to get a representative sampling of feature values, all absolute
gradient image, RLM, and COM features were extracted with three different image bit
depths: 2, 6, and 10. The intensity histogram features were extracted using a bit depth of 12,
and the geometric features are unaffected by bit depth. In total, for 11 different, equally
spaced HU cutoffs between -1000 and 0, 328 image features were extracted for every GTV.

32

Quantifying reproducibility
For a particular feature, let x be a vector of that feature’s values across the patients’
first scan. Let y be a vector of that feature’s values across the patients’ second scan. The
concordance correlation coefficient (CCC) (45), a commonly used measure of reproducibility
and inter-rater reliability, is then defined as:

CCC ≡ 1 −

( x − y)2

σ x2 + σ y2 + ( µ x − µ y ) 2

(3.1)

As suggested by McBride (66), we defined reproducible features as those features
with CCC ≥ 0.90. Like Kumar et al. (23), we also considered selecting features based on
their dynamic ranges (DRs), but we noticed a strong overlap between the feature sets that
passed a DR cutoff and the feature sets that passed a CCC. Plots of CCC vs. DR −2 were
very linear (Figure 3.2), so we suspected an approximate relationship between the two
metrics existed. Therefore, using reasonable assumptions (verified by our feature data
values), we searched for an explanation.
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Figure 3.2: Feature CCC vs. 1/DR2 for 328 features extracted from M2 T50 test-retest
test
scans.
For a particular feature, starting with Equation 3.1,, assume that the first scans and
2
2
2
the second scans have the same means and variances (i.e. µ x = µ y ≡ µ p and σ x = σ y ≡ σ p ).

The CCC then simplifies:

CCC ≈ 1 − ( x − y)2 / 2σ p2

(3.2)

Define the range for the feature: ∆f ≡ max(max( x ), max( y )) − min(min( x ), min( y ))

(3.3)

Define the dynamic range of the feature: DR ≡ ∆f / x − y

(3.4)

Assume: δ i

N ( 0, σ δ2 ) and y ≡ x + δ ⇒ δ = y − x , then:

δ = 2 / πσ δ

(3.5)

δ 2 = σ δ2

(3.6)
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If σ p

σ δ , then for uniform, Gaussian, Poisson, exponential, and other distributions:
(3.7)

∆f ∝ σ p
Substituting Equation 3.6 into Equation 3.2 gives: 1 − CCC ∝ σ δ2 / σ p2

(3.8)

Substituting Equations 3.5 and 3.7 into Equation 3.4 gives: DR ∝ σ p / σ δ

(3.9)

Therefore: 1 − CCC ∝ DR −2

(3.10)

This explains the observations of Figure 3.2. It also implies that a cutoff on CCC
implicitly implies a corresponding cutoff on DR. Therefore, to avoid redundant cutoffs, we
chose to only use a CCC constraint since ∆f is sensitive to outliers.
Thus, for each of the six machine / image type combinations (M1 T50, M2 T50, M1
AVG, M2 AVG, M3, and M4), we used the CCC constraint to identify which of the 328
features extracted were reproducible. This was done for each of the 11 HU cutoffs between 1000 and 0. In order to find features that were reproducible across multiple machines, the
intersection of individual machine reproducible feature sets was taken.
To quantify how machine-sensitive feature reproducibility is, for two machines with
identical image types, let A be the set of reproducible features on one machine and B be
the set of reproducible features on the other. In terms of these variables, the Dice similarity
coefficient (DSC) (67) and the Jaccard index (JI) (68) are defined as follows:

DSC ( A, B) ≡

JI ( A, B) ≡

2 A∩ B
A+B

(3.11)

A∩ B
A∪ B

(3.12)

To quantify inter-machine feature selection agreement, each of these values was
calculated using machine M1 and machine M2 for both T50 images and AVG images.
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Finding reproducible, non-redundant features
Applying the CCC reproducibility constraint and taking the feature set intersection
across multiple machines substantially reduced the total number of candidate features.
However, many of the remaining features were strongly correlated with one another, and it
would be useful to find a non-redundant subset of these features. Therefore, for a set of
features F that is reproducible across N machines, let ρ k (i ) = concordance correlation
coefficient for feature i on machine k , and let rk (i, j ) be the sample Spearman’s rank
correlation coefficient between feature i and feature j on machine k . Next, define:

ρ (i) =

1 N
∑ ρk (i)
N k =1

(3.13)

d k (i, j ) = 1 − rk (i, j )

d (i, j ) =

(3.14)

1 N
∑ dk (i, j )
N k =1

(3.15)

Where ρ (i ) is the mean CCC for feature i across all N machines, d k (i, j ) is the
similarity distance between features i and j on machine k , and d (i, j ) is the mean
similarity distance between features i and j across all N machines.
Using these definitions, the similarity distance between all of the feature pairs of F
can be calculated for each machine, and the mean similarity distances between the feature
pairs of F can be established. The features present in F can then be hierarchically clustered
based on the d (i, j ) distance function. By clustering until a threshold value is reached,
several non-redundant, reproducible clusters can be identified. By picking the feature from
each cluster with the highest average reproducibility across machines (Equation 3.13), a set
of features that are non-redundant and reproducible across multiple machines can be
identified. This process was performed for several different HU cutoffs and machine / image
type combinations. In each case, the clustering algorithm used an average linkage function
and an average mean similarity distance clustering threshold of 0.1.
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3.3 Results
Single Machine Reproducibility
Figure 3.3 shows the percent of the 328 image features that had a certain CCC value
or higher when no voxels are removed from the GTV prior to feature extraction. Intersections
with CCC = 0.90 indicate the number of features that were considered reproducible. In the
figure, the three image types track each other initially, but then diverge to have considerably
different levels of reproducibility. The cine 4D-CT average images were the most
reproducible and had curves that bent down the least; 90.5% of the features were
reproducible for M1 AVG and 94.5% of the features were reproducible for M2 AVG. The cine
4D-CT T50 scans were the next most reproducible (M1 T50 = 75.0% pass; M2 T50 = 71.0%
pass), and the helical 3D-CT breath-hold scans had the fewest number of reproducible
features (M3 = 61.0% pass). Images interpolated with uniform voxel sizes did not improve
the number of reproducible features (M4 = 57.3% pass). Figure 3.3 was generated multiple
times using various HU cutoffs to generate Figure 3.4. In Figure 3.4, it is apparent that for all
machines and image types, as the HU cutoff goes down the number of reproducible features
tends to goes up. This trend implies that for maximum feature reproducibility, no HU cutoff
should be used.
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Figure 3.3: Percent of GTV image features with a CCC greater than or equal to the
indicated value.

Multi-machine reproducibility
For each of the data points in Figure 3.4,
4, each machine has a set of reproducible
features. By taking the intersection of these sets we found features that were reproducible
across multiple machines. Figure 3.5
5 shows the reproducible feature percentage for several
different multi-machine
machine combinations. The same trend is noted: the number of multi-machine
multi
reproducible features increases as the HU cutoff is decreased. At an HU cutoff of -1000 (i.e.
no cutoff), forr average scans, 86.3% of features were reproducible across both machines
(M1 and M2), for T50 scans, 52.1% of features were reproducible across both machines,
and for “single phase” scans (M1 T50, M2 T50, and M3), 42.1% of features were
reproducible acrosss all three machines. Exchanging M3 with M4 did not appreciably affect
the number of multi-machine
machine reproducible features (41.5%).
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Figure 3.4: Percent of features that are reproducible (CCC ≥ 0.90) when vox
voxels with CT
numbers less than the specified HU cutoff are removed from the GTV before feature
extraction.
To investigate if feature reproducibility is machine-sensitive,
machine
Figure 3.6
3. displays M1
CCC vs. M2 CCC for both T50 and AVG scans (no HU cutoff). Points
Points falling to the right of
the vertical lines correspond to reproducible features on M1, and points falling above the
horizontal lines correspond to reproducible features on M2. Venn diagram areas indicate the
relative number of reproducible features that were common or unique for the two machines.
The Dice similarity coefficients and Jaccard indices and indicate that T50 feature
reproducibility is relatively machine-sensitive
machine sensitive (DSC = 0.71, JI = 0.55) while AVG feature
reproducibility is relatively machine-insensitive
machine insensitive (DSC = 0.93, JI = 0.87). However, if HU
cutoffs are applied, both image types begin to show machine-sensitivity.
machine sensitivity. For example, an HU
cutoff of 0 gives DSC = 0.61 and JI = 0.44 for T50 images and DSC = 0.54 and 0.37 for AVG
images.
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Figure 3.5: Percent of features that are reproducible across all of the machines
specified given a particular HU cutoff.
cutoff
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Figure 3.6: M1 CCC vs. M2 CCC. Panel a) depicts the relationship for T50 scans and
panel b) depicts the relationship for AVG scans. Venn diagrams, Dice similarity
coefficients (DSC), and the Jaccard indices (JI) are displayed. The CCC ≥ 0.90 cutoff is
shown for both axes. No HU cutoff was used.

Reproducible, non-redundant feature sets
Across single phase scans (M1 T50, M2 T50, and M3), 42.1% or 138 out of 328
image features were reproducible on all machines (no HU cutoff). The cluster heat map (69)
in Figure 3.7 shows the values of these 138 reproducible features for the 25 M3 test-retest
pairs (50 scans). Repeated horizontal patterns present in the cluster heat map indicate that
that there is considerable feature redundancy, especially for the RLM grey level
nonuniformity (GLNU) features and RLM run length nonuniformity (RLNU) features.
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Figure 3.7: Cluster heat map representation of the M3 scans using the 138 features
that passed the reproducibility cutoff on single phase scans. No HU cutoff was used.
Green cells correspond to a feature value above the mean, red cells correspond to
feature values below the mean, and the color intensity indicates the deviation
magnitude. Image features (rows) were clustered using the Pearson’s distance metric,
and patient scans (columns) were clustered using a Euclidean distance metric. Both
used an average linkage function. Scans are labeled such that the number indicates
the test-retest pair; ‘A’ and ‘B’ represent scan #1 and scan #2, respectively.
Dendrograms indicate the hierarchical relationships both between the features and
between the scans
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To address this, Equation 3.14 was used to quantify how redundant two features are
on a particular machine. The distribution of feature similarity distances ( d k (i, j ) ) for different
machines is shown in Figure 3.8 (no HU cutoff). Feature pairs with distances near zero are
very redundant; feature pairs with distances near one are non-redundant. The different
shape and increased number of non-redundant feature pairs for Figure 3.8b (M2 T50)
compared to Figure 3.8a (M1 T50) indicate that feature redundancy is moderately machinesensitive. Similar histograms (data not shown) show different feature similarity distance
distributions both for M1 T50 vs. M1 AVG and M2 T50 vs. M2 AVG, indicating that feature
redundancy is also image type sensitive. In Figure 3.8c (M3 data) both the machine and
image type are changed compared to Figure 3.8a and Figure 3.8b. Thus, its feature pair
distance distribution appears quite different; relatively more feature pairs are either very
redundant or very non-redundant, with fewer feature pairs in between. Figure 3.8d uses
Equation 3.15 and shows the distribution of the mean similarity distances ( d (i, j ) ) across
the three machines. Its final (0.9 to 1.0) distance bin is relatively empty, implying that it is
rare for a feature to be strongly non-redundant across all three machines.
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Figure 3.8: Panels a), b), and c) show histograms of the feature pair similarity
distances for the 9453 feature pairs possible from the 138 features that passed the
reproducibility cutoff for all single phase scans with no HU cutoff. Panel d) shows the
distribution of mean feature similarity distances.
Figure 3.9 shows a dendrogram generated from the hierarchical clustering of the 138
features that were reproducible across all single phase scans (no HU cutoff). It used the
mean similarity distance of a feature pair as a distance function (distribution shown in Figure
3.8d). It also used an average linkage function, so the distance between two feature clusters
is the average mean similarity distance, and a cutoff value of 0.1 was selected to find a finite
number of relatively non-redundant feature clusters (in this case 23).
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Figure 3.9: Dendrogram illustrating hierarchical feature clustering using the average
mean similarity distance between feature clusters as a distance metric. The average
mean similarity distance between two clusters is the average of the mean similarity
distances between the elements of each cluster (see inset). Two clusters merge
(horizontal bar) when the average mean similarity distance between their constituent
features becomes greater than the y-value indicated in the diagram. There are 23
clusters at the average mean similarity distance cutoff of 0.1 (red line). Feature values
came from the 138 features that passed the reproducibility cutoff on all single phase
scans (no HU cutoff).
This whole process (identifying multi-machine reproducible features and clustering to
a threshold) was done for 4 different multi-machine combinations and 11 different HU
cutoffs. All used the same 0.1 clustering threshold. The results are displayed in Figure 3.10,
and show a similar trend to those in Figure 3.5: as the HU cutoff goes down, the number of
non-redundant feature clusters goes up. Therefore, we used HU cutoff  .1000 and
generated a list of reproducible, non-redundant features for each of the 4 multi-machine
combinations in Figure 3.10. See Table 3.3. Each entry in the table is a representative
feature from one of the reproducible, non-redundant clusters of the multi-machine
combination indicated. For cine 4D-CT average images and for cine 4D-CT T50 images, we
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recommend columns 1 and 2, respectively.

For “single phase” mixed cine 4D-CT
4D
T50

images and helical 3D-CT
CT breath-hold
breath hold images, we recommend column 3. For helical 3D-CT
3D
breath-hold
hold images we recommend column 4.

non redundant feature clusters (average mean similarity
Figure 3.10: Number of non-redundant
distance > 0.1) generated by hierarchically clustering features that are reproducible
across all of the machines specified.
specified
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Table 3.3: Multi-machine reproducible and non-redundant feature lists. Coordinates
indicate either a direction (RLM) or a displacement (COM); BD indicates bit depth; VA
ratio, volume to area ratio; GEO, geometric; IHIST, intensity histogram; IGR, absolute
gradient image; RLM, run length matrix; COM, co-occurrence matrix; p10tile, 10th
percentile; FxR, fraction in runs; SRE, short run emphasis; LRE, long run emphasis;
RLNU, run length nonuniformity; GLNU, grey level nonuniformity; PNonZero,
probability non-zero.
M1 AVG & M2 AVG
(38 features)

M1 T50 & M2 T50
(28 features)

M1 T50 & M2 T50 & M3
(23 features)

M3
(33 features)

IHIST entropy

GEO VA ratio

GEO VA ratio

GEO volume

IHIST kurtosis

IHIST entropy

GEO volume

IHIST kurtosis

IHIST max

IHIST kurtosis

IHIST kurtosis

IHIST p10tile

IHIST mean

IHIST p10tile

IHIST p10tile

IHIST skewness

IHIST min

IHIST p1tile

IHIST skewness

IGR BD10 PNonZero

IHIST p10tile

IHIST skewness

IGR BD10 Skewness

IGR BD6 Mean

IHIST p1tile

IGR BD2 Variance

IGR BD6 Mean

RLM BD10 FxR (1,0,1)

IHIST p99tile

IGR BD6 Mean

RLM BD10 LRE (1,0,0)

RLM BD10 FxR (1,0,-1)

IHIST variance

RLM BD10 RLNU (0,1,0)

COM BD10 AngScMom (-1,0,0)

RLM BD10 FxR (-1,1,1)

IGR BD10 Variance

RLM BD10 SRE (1,0,0)

COM BD10 Correlation (0,-1,0)

RLM BD10 FxR (1,1,-1)

IGR BD2 Kurtosis

COM BD10 AngScMom (-1,0,0)

COM BD10 Correlation (-1,0,0)

RLM BD10 LRE (0,1,0)

IGR BD2 Variance

COM BD10 Correlation (-1,0,0)

COM BD10 DifEntrp (-1,0,0)

RLM BD10 LRE (1,0,0)

IGR BD6 Skewness

COM BD10 DifEntrp (0,-1,0)

COM BD10 Entropy (-1,0,0)

RLM BD10 LRE (1,1,0)

RLM BD10 LRE (0,1,-1)

COM BD10 DifEntrp (-1,0,0)

COM BD10 InvDfMom (0,-1,0)

RLM BD10 LRE (-1,1,0)

RLM BD10 RLNU (0,0,1)

COM BD10 Entropy (-1,0,0)

COM BD10 InvDfMom (-1,0,0)

RLM BD6 SRE (0,1,0)

RLM BD2 FxR (1,1,0)

COM BD10 InvDfMom (0,-1,0)

COM BD10 SumEntrp (-1,0,0)

RLM BD6 SRE (1,1,0)

RLM BD2 FxR (-1,1,-1)

COM BD10 InvDfMom (-1,0,0)

COM BD10 SumOfSqs (0,-1,0)

RLM BD6 SRE (1,1,-1)

RLM BD2 RLNU (1,0,-1)

COM BD10 SumEntrp (-1,0,0)

COM BD2 SumVarnc (0,0,-1)

COM BD10 AngScMom (-1,0,0)

RLM BD2 SRE (1,1,0)

COM BD10 SumOfSqs (0,-1,0)

COM BD6 DifEntrp (-1,0,0)

COM BD10 Correlation (0,-1,0)

RLM BD2 SRE (-1,1,0)

COM BD2 SumOfSqs (0,0,-1)

COM BD6 DifVarnc (-1,0,0)

COM BD10 DifEntrp (0,0,-1)

RLM BD6 GLNU (0,0,1)

COM BD2 SumVarnc (0,0,-1)

COM BD6 Entropy (0,-1,0)

COM BD10 DifEntrp (-1,0,0)

COM BD10 AngScMom (0,0,-1)

COM BD6 Contrast (0,0,-1)

COM BD6 InvDfMom (0,0,-1)

COM BD10 Entropy (0,-1,0)

COM BD10 Correlation (0,-1,0)

COM BD6 Correlation (0,0,-1)

COM BD6 InvDfMom (0,-1,0)

COM BD10 InvDfMom (0,0,-1)

COM BD10 DifVarnc (-1,0,0)

COM BD6 DifEntrp (0,-1,0)

COM BD10 InvDfMom (0,-1,0)

COM BD10 Entropy (0,-1,0)

COM BD6 DifEntrp (-1,0,0)

COM BD10 InvDfMom (-1,0,0)

COM BD10 InvDfMom (0,-1,0)

COM BD6 DifVarnc (0,-1,0)

COM BD10 SumEntrp (0,0,-1)

COM BD10 SumEntrp (0,0,-1)

COM BD6 DifVarnc (-1,0,0)

COM BD10 SumEntrp (-1,0,0)

COM BD2 Contrast (0,0,-1)

COM BD6 InvDfMom (0,0,-1)

COM BD2 SumVarnc (0,0,-1)

COM BD2 Contrast (-1,0,0)

COM BD6 Correlation (-1,0,0)

COM BD6 AngScMom (0,-1,0)

COM BD6 Entropy (-1,0,0)

COM BD6 DifEntrp (0,0,-1)

COM BD6 InvDfMom (0,-1,0)

COM BD6 DifEntrp (0,-1,0)

COM BD6 InvDfMom (-1,0,0)

COM BD6 DifEntrp (-1,0,0)

COM BD6 SumVarnc (0,0,-1)

COM BD6 DifVarnc (0,0,-1)
COM BD6 DifVarnc (0,-1,0)
COM BD6 Entropy (0,0,-1)
COM BD6 InvDfMom (0,-1,0)
COM BD6 InvDfMom (-1,0,0)
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To confirm that the recommended feature sets are non-redundant, we generated a
cluster heat map (Figure 3.11) for all single phase scans (32 M1 T50 scans, 30 M1 T50
scans, and 50 M3 scans) using the 23 features from Table 3.3, column 3. The absence of
repeated vertical patterns in the heat map indicates that the selected features are nonredundant. Furthermore, blinded to the fact that test-retest pairs were present, 55 out of 56
test-retest pairs were correctly placed adjacent to one another in the figure. This indicates
that the selected features were sufficiently informative to accurately match and distinguish
patients.
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Figure 3.11: Cluster heat map representation of all scans from M1 T50, M2 T50, and
M3 (no HU cutoff). Green cells correspond to a feature value above the mean, red cells
correspond to feature values below the mean, and the color intensity indicates the
deviation magnitude. For readability, orientations are reversed from Figure 3.6. Each
of the 23 features shown had the highest average CCC from one of the 23
independent clusters shown in Figure 3.9. Features (columns) were clustered using
the Pearson’s distance metric, and patient scans (rows) were clustered using a
Euclidean distance metric. Both used an average linkage function. Scans are labeled
such that the number indicates the test-retest pair; ‘A’ and ‘B’ represent scan #1 and
scan #2, respectively. Dendrograms indicate the hierarchical relationships between
the features and between the scans.
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3.4 Discussion
Our study was strongly inspired by Kumar et al. (23), however, there are several key
differences. We applied their techniques to several different machines and image types and
studied how different machines and image types affected feature reproducibility and
redundancy. We also studied feature reproducibility as a function of HU cutoff (i.e. GTV
pruning) and omitted the feature dynamic range requirement. Additionally, we developed a
strategy to integrate the findings to produce a multi-machine reproducible and nonredundant feature set. We also omitted some of the patients used by Kumar et al. (23), used
a different set of image features, and had a different semi-automated contouring process.
These methodological differences could explain why our CCC values were relatively higher,
leading us to chose to use a reproducibility cutoff of 0.90 instead of 0.85 (23).
CT image type was found to strongly affect feature reproducibility (Figure 3.3, Figure
3.4, and Figure 3.5). Features from cine 4D-CT average images were substantially more
reproducible than those associated with T50 images, and T50 associated features were
somewhat more reproducible than breath-hold helical 3D-CT features. This may seem
counter-intuitive since T50 images are intended to “freeze” motion. However, because
average images are an average of 10 image phase reconstructions, they are less
susceptible to photon noise and various 4D-CT artifacts (70-72). As for the breath-hold CTs,
it is difficult to draw conclusions since the machine, image type, and convolution kernel
varied simultaneously compared to the other datasets. However, M4 did not appear to have
better reproducibility than M3. That is, no significant reproducibility improvements were
observed when scans were interpolated to have a uniform voxel size. If raw CT data were
available it may have been possible to reconstruct images with a standard voxel size and
achieve better results.
As the HU cutoff goes down (i.e. as fewer low-intensity GTV voxels are pruned), we
found 1) reproducibility becomes less machine-sensitive (Figure 3.6), 2) individual machine
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reproducibility goes up (Figure 3.4), 3) multi-machine reproducibility goes up (Figure 3.5),
and 4) the number of multi-machine, non-redundant clusters goes up (Figure 3.10). This last
finding is particularly interesting since it implies that the low intensity voxels contain nonredundant information. Since the vast majority of the low intensity voxels appear at the tumor
periphery, these findings indicate that the periphery contains valuable non-redundant
information which can be used to discriminate tumors. This is understandable, since noncontrast-enhanced CT has limited soft tissue contrast; if the periphery is removed, there are
fewer intensity variations to extract independent features from. Thus, we recommend against
removing voxels based on their intensity values as a pre-processing step to feature
extraction. This is in opposition to the NSCLC CT protocol of Ganeshan et al. (39, 40), but
we believe that it is likely due to methodological differences. In their studies, directionally
independent first-order statistics (e.g. entropy and uniformity) were extracted from the filtered
2D image slice that had the largest transverse tumor length. In our work, features are
extracted from the intensity histogram, absolute gradient image, RLM, and COM values
evaluated over the entire unfiltered GTV. Therefore, as a caveat, we should emphasize that
our tumor pre-processing (i.e. pruning) protocols and feature set recommendations are only
applicable to similar datasets (non-contrast-enhanced NSCLC CT images) using similar
image features (Table 3.2).
One limitation of our study is that all semi-automated contouring was done by a
single individual (the primary author). Ideally, multiple individuals could contour each GTV
and operator sensitivity could be studied. Alternatively, one of several automated
segmentation techniques could be used to possibly increase reproducibility (73). In the
future it would also be useful to study the reproducibility of additional image features and the
effect of convolution kernels. Another limitation is that all of the machines used in our study
are GE machines. Ideally, multiple machines from various manufacturers should be tested to
see if there are any systematic or random feature value variations between them. Finally, a
key point to note is that our study only assessed intra-machine reproducibility. Multi-machine
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reproducible features were defined as features that have good intra-machine reproducibility
on multiple machines. Because patients were not test-retest imaged on multiple scanners,
we cannot directly assess inter-machine reproducibility (i.e. agreement of feature values
between machines). For ethical reasons, this necessitates a phantom, and there are several
good candidates for future work. Court et al. (74) created a model of a real lung tumor using
rapid prototyping, placed it into an anthropomorphic phantom, and moved it to match
recorded tumor motion trajectories. This phantom would be very useful to study how motion
affects feature reproducibility across multiple machines. In a separate application of rapid
prototyping, another group has developed a way to independently control the CT number of
every voxel of a phantom (75). Unlike a solid phantom, this model could be used to study
image feature fidelity in the presence of subtle changes in voxel intensity and indistinct
tissue boundaries.
3.5 Conclusion
This study integrated multiple NSCLC test-retest CT datasets to identify informative,
non-redundant image features with high intra-machine reproducibility on multiple machines.
Image feature quality was best for average 4D-CT images, and the tumor periphery was
found to play an important role in tumor discrimination. Further advanced phantom studies
are needed to investigate inter-machine image feature reproducibility.
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Chapter 4: Discussion
4.1 Summary and Conclusions
Chapter 2 showed that quantitative image feature models derived from existing pretreatment CT images could successfully predict NSCLC tumor shrinkage, an indicator of
treatment efficacy and future survival.
Chapter 3 showed that image feature reproducibility and redundancy depended on
both the CT machine and the CT image type. For each of the image types (end-exhale 4DCT, average 4D-CT, and helical breath-hold 3D-CT) multiple NSCLC test-retest CT datasets
were integrated to identify informative, non-redundant image features with high intramachine reproducibility on multiple machines. Pruning of low intensity voxels showed that
the tumor periphery plays an important role in tumor discrimination. Compared to end-exhale
4D-CT and breath-hold 3D-CT, average 4D-CT derived image features showed superior
multi-machine reproducibility and are the best candidates for clinical correlation.
4.2 Evaluation of Hypotheses and Specific Aims
Specific aims 1 and 2 were successfully completed by the work presented in Chapter
2 and resulted in the confirmation of the first hypothesis: CT image features extracted from
pre-treatment NSCLC tumors can be used to predict tumor shrinkage in response to therapy.
Specific aims 3 and 4 were successfully completed by the work presented in Chapter
3 and resulted in the confirmation of the second hypothesis: various selection metrics can
identify a small subset of “ideal” image features for each of several different CT image types.
4.3 Future Research and Applications
Chapter 2 supports the findings of (41) and (46) which showed that quantitative
image features could be used to make clinically relevant predictions for NSCLC patients. As
our survival outcome data is currently unavailable, we are unable to develop a binary
classifier to predict survival at present. However, in the future when this data is available, we
could develop such a model. Since our dataset had more uniform treatment and imaging,
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comparing its AUC to their findings could indicate how important treatment uniformity and
imaging uniformity are for accurate radiomics survival prediction. This could have important
applications when planning future prospective radiomics studies.
A limitation of our study in Chapter 3 is that a test-retest patient is only scanned on
one machine. Therefore, we only have information to assess intra-machine reproducibility.
To simultaneously assess both intra- and inter-machine reproducibility, a patient needs to be
imaged at least twice on two machines (i.e. four total scans). This is not ethically justifiable,
so a phantom is required. To examine how tumor motion affects inter-machine
reproducibility, a 3D printed moveable phantom could be used (74). To how much fine tumor
detail affects inter-machine reproducibility, another 3D printed phantom with finely controlled
voxel CT numbers could be used (75). This later approach is a better simulation of tumor
visual complexity, but it does not include tumor motion. One possible solution to this is to
print test-retest image pairs directly into a CT number accurate phantom. By scanning this
phantom on multiple machines, human test-retest scans on multiple machines could be
simulated. Additionally, since the printed images already have motion-induced changes, this
static phantom would allow for the simultaneous investigation of fine tumor detail and
motion. This could be applied in future radiomics studies to find image feature sets that
simultaneously optimize intra- and inter-machine reproducibility.
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